Zhi Tong Cai Jing·2025-12-25 10:36Core Viewpoint - Fudan Zhangjiang (688505.SH) has received approval from the National Medical Products Administration for the clinical trial application of FZ-P001 sodium for intraoperative visualization of malignant lesions in known or suspected lung cancer patients [1] Group 1: Product Development - FZ-P001 sodium is a first-class new chemical compound independently developed by the company, characterized as an innovative photosensitizer [1] - The active ingredient is a molecule formed by the conjugation of a folate receptor-targeting small molecule and a phthalocyanine photosensitizer, which can target malignant tumor tissues with high expression of folate receptor alpha (FRα) and fluoresce in the near-infrared range [1] Group 2: Clinical Application - The company plans to utilize this drug to develop intraoperative fluorescence guidance technology, indicating the residual malignant tumor tissue and margin status during surgery [1] - The aim is to enhance the surgical resection effectiveness for related solid tumors, such as ovarian cancer and lung cancer, providing an innovative solution for precise navigation in tumor surgery with molecular targeting specificity and multidimensional biological sensing [1]